BIOMAT Database Logo BIOMAT Database Logo

[Parkinson's syndrome and L-dopa]. 1971

F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
L-dopa in Parkinson's syndrome.
February 1969, The New England journal of medicine,
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
[L-dopa in Parkinson's syndrome].
May 1971, Revista brasileira de medicina,
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
L-dopa in parkinson's syndrome.
July 1969, The New England journal of medicine,
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
[L-dopa effect in Parkinson's syndrome].
February 1971, Zeitschrift fur Allgemeinmedizin,
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
[Action of L-dopa in Parkinson's syndrome].
February 1971, Revista clinica espanola,
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
[Treatment of Parkinson's syndrome with L-dopa].
May 1970, Schweizerische medizinische Wochenschrift,
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
[Treatment of Parkinson's syndrome with L-dopa].
June 1972, Lakartidningen,
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
[L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
August 1972, Deutsche medizinische Wochenschrift (1946),
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
[Parkinson's syndrome. 7. Experiences with L-dopa-treatment].
October 1970, Lakartidningen,
F Pompeu, and M Sztajnberg, and I Teixeira, and S Carneiro, and I Schulz, and S Ribeiro, and H Vasconcelos, and E Albuquerque
[L-Dopa in Parkinson's-syndrome. New therapeutic attack?].
November 1970, Therapie der Gegenwart,
Copied contents to your clipboard!